Fig. 8

The therapeutic efficacy and toxicity of CREBZF-mRNA-NPs for BC in vivo. (A) Schematic diagram illustrated the timeline of tumor planted and injection of PBS, Control NPs, or CREBZF-mRNA-NPs in CREBZF-null MCF-7 nude mice. After 8 days of tumor inoculation, mice received NPs injection every 3 days for 7 cycles. (B) Tumor growth curves of CREBZF-null MCF-7 xenograft mice after randomly injection of PBS, Control NPs, or CREBZF-mRNA-NPs group. (C) Body weight of nude mice in indicated group. (D) CREBZF, ADAR1, circPAPD4, Ki-67, and TUNEL expression levels of xenografts in indicated groups were evaluated by immunofluorescence and FISH analysis; Scale bar: 20 μm. (E) Represented H&E stained images of major organs after treated with PBS, Control NPs, or CREBZF-mRNA-NPs; Scale bar: 20 μm. (F) Serum levels of ALT, AST, Cr, and BUN in indicated groups after 24 h from i.v. injection. n = 3 mice each group. Data are presented as means ± SD. ***p < 0.001.